References of "SAUTOIS, Brieuc"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailPrevention primaire et secondaire du cancer colorectal
Polus, Marc ULg; Piront, Patricia ULg; Jerusalem, Guy ULg et al

in Revue Médicale de Liège (2003), 58(4), 247-53

Colorectal cancer is really a public health problem. The authors review the literature about the environmental factors leading to colorectal cancer. Chemoprevention of colorectal cancer is also discussed ... [more ▼]

Colorectal cancer is really a public health problem. The authors review the literature about the environmental factors leading to colorectal cancer. Chemoprevention of colorectal cancer is also discussed, particularly by aspirin and non steroidal anti-inflammatory drugs. Development of specific cyclooxygenase-2 inhibitors constitutes a promising research's field. Secondary prevention by coloscopy and polypectomy must lead to a lower rate of colorectal cancer disease and improvement of mortality. [less ▲]

Detailed reference viewed: 215 (2 ULg)
Full Text
Peer Reviewed
See detailRadiothérapie métabolique des douleurs osseuses métastatiques
Hustinx, Roland ULg; Sautois, Brieuc ULg; Jerusalem, Guy ULg et al

in Médecine et Hygiène (2003), 61

La radiothérapie métabolique des métastases osseuses est un traitement palliatif de la douleur. Cet objectif est rempli dans la grande majorité des cas, sans effets secondaires cliniquement ressentis par ... [more ▼]

La radiothérapie métabolique des métastases osseuses est un traitement palliatif de la douleur. Cet objectif est rempli dans la grande majorité des cas, sans effets secondaires cliniquement ressentis par le patient. Tous les patients en dissémination osseuse ne peuvent cependant bénéficier de cette approche qui, lorsqu'elle est choisie, doit toujours être appliquée dans un cadre multidisciplinaire. Les lésions accessibles à ce traitement doivent avoir démontré leur caractère ostéocondensant en scintigraphie. La fonction rénale et la réserve médullaire sont des paramètres importants, l'élimination des radiopharmaceutiques étant urinaire et leur toxicité, médullaire. Les situations particulières telles que risque fracturaire important ou compression médullaire sont des contre-indications. Le traitement est simple dans son principe et dans sa réalisation. Il permet une amélioration très significative de la qualité de vie, tout en réalisant des économies substantielles en terme de coût de santé publique. [less ▲]

Detailed reference viewed: 105 (5 ULg)
Full Text
Peer Reviewed
See detailLa carcinomatose hepatique du cancer colorectal: actualites therapeutiques
Polus, Marc ULg; Honore, Pierre ULg; De Roover, Arnaud ULg et al

in Revue Médicale de Liège (2002), 57(12), 771-8

Important progress has been made in the treatment of liver metastases of advanced colorectal cancer. Surgery with curative intent, when possible, shows evidence of prolonged survival. Response rate and ... [more ▼]

Important progress has been made in the treatment of liver metastases of advanced colorectal cancer. Surgery with curative intent, when possible, shows evidence of prolonged survival. Response rate and overall survival can be improved with modern polychemotherapy. Cytotoxic drug combinations and sequential treatments sometimes make surgery possible for initially non resectable lesions. Impact of loco-regional treatment such as hepatic arterial infusion chemotherapy must be defined in randomised trials. Radiofrequency ablation is also currently evaluated in clinical trials. In this review the benefit of each treatment is discussed. [less ▲]

Detailed reference viewed: 285 (10 ULg)
Full Text
Peer Reviewed
See detailComment je traite ... par hormonotherapie des patientes developpant des complications thrombo-emboliques lors du traitement d'un cancer du sein par tamoxifene
Pelerin, D.; Silvestre, R. M.; Jerusalem, Guy ULg et al

in Revue Médicale de Liège (2002), 57(12), 755-6

Thromboembolic complications are well known side effects of treatment with tamoxifen in patients with breast cancer. The authors review the pathophysiology and the risk factors that increase the ... [more ▼]

Thromboembolic complications are well known side effects of treatment with tamoxifen in patients with breast cancer. The authors review the pathophysiology and the risk factors that increase the probability to develop these complications. The most appropriate treatment is discussed. [less ▲]

Detailed reference viewed: 73 (0 ULg)
Full Text
Peer Reviewed
See detailComment je traite.... Le cancer avance du pancreas par une approche innovante dirigee contre les nouvelles cibles
Polus, Marc ULg; Bours, Vincent ULg; Jerusalem, Guy ULg et al

in Revue Médicale de Liège (2002), 57(7), 428-32

A better knowledge of fundamental mechanisms of carcinogenesis allows the development of novel therapeutic tools specifically targeting the cancer cell. Our understanding of cellular and molecular ... [more ▼]

A better knowledge of fundamental mechanisms of carcinogenesis allows the development of novel therapeutic tools specifically targeting the cancer cell. Our understanding of cellular and molecular mechanisms controlling cellular cycle and cell survival is an important step for new anti-cancer treatments. This review will focus on new therapeutic's strategies in advanced pancreatic cancer. [less ▲]

Detailed reference viewed: 80 (3 ULg)
Full Text
Peer Reviewed
See detailComment je traite.... Un cancer du pancreas avance
Polus, Marc ULg; Jerusalem, Guy ULg; Sautois, Brieuc ULg et al

in Revue Médicale de Liège (2002), 57(3), 131-4

Median survival of advanced pancreatic cancer is about three months. Unfortunately, chemotherapy is not a curative approach. Chemotherapy improves the quality of life and overall survival compared to best ... [more ▼]

Median survival of advanced pancreatic cancer is about three months. Unfortunately, chemotherapy is not a curative approach. Chemotherapy improves the quality of life and overall survival compared to best supportive care. Nevertheless, as the overall survival remains disappointing, clinical research must ongoing to define better treatment regimen. [less ▲]

Detailed reference viewed: 109 (5 ULg)
Full Text
Peer Reviewed
See detailEtude clinique du mois. Radio-chimiotherapie et chimiotherapie adjuvante apres resection a visee curative du cancer du pancreas: resultats de l'etude randomisee ESPAC-1
Polus, Marc ULg; Jerusalem, Guy ULg; Sautois, Brieuc ULg et al

in Revue Médicale de Liège (2002), 57(2), 119-22

The prognosis of pancreatic adenocarcinoma remains poor, with a 5-year survival rate lower than 5%. Resection, the gold standard treatment, can be performed in less than 15% of patients. Following surgery ... [more ▼]

The prognosis of pancreatic adenocarcinoma remains poor, with a 5-year survival rate lower than 5%. Resection, the gold standard treatment, can be performed in less than 15% of patients. Following surgery, the median survival is 12 months for the most favourable cancer patients. Adjuvant treatment have attempted to improve results. However, chemotherapy, radiotherapy and multimodal treatments don't have demonstrated a clear advantage in controlled trials. We will discuss results of the current trials in this topic. The randomised trial of the European Study Group for Pancreatic Cancer (ESPAC) recently published in the Lancet revealed a potential benefit of adjuvant chemotherapy. A critical analysis of the publication showed, however, that definitive conclusions of this trial must be interpreted with caution. [less ▲]

Detailed reference viewed: 58 (2 ULg)
Full Text
Peer Reviewed
See detailPrévention et traitement des nausées et vomissements après chimiothérapie anticancéreuse
Brasseur, Edmond ULg; Silvestre, Rose-Marie; Jerusalem, Guy ULg et al

in Médecine et Hygiène (2002), 60

Detailed reference viewed: 90 (14 ULg)
Full Text
Peer Reviewed
See detailOptimization of recombinant human erythropoietin therapy after allogeneic hematopoietic stem cell transplantation.
Baron, Frédéric ULg; Sautois, Brieuc ULg; Baudoux, Etienne ULg et al

in Experimental hematology (2002), 30(6), 546-54

OBJECTIVE: Allogeneic hematopoietic stem cell transplantation (HSCT) is associated with prolonged anemia caused by defective erythropoietin (Epo) production. We enrolled 34 recipients of an allogeneic ... [more ▼]

OBJECTIVE: Allogeneic hematopoietic stem cell transplantation (HSCT) is associated with prolonged anemia caused by defective erythropoietin (Epo) production. We enrolled 34 recipients of an allogeneic HSCT in three consecutive trials to determine the optimal utilization of recombinant human erythropoietin (rhEpo) therapy in this setting. MATERIALS AND METHODS: In the first trial (n = 7), rhEpo 1400 U/kg/week was given from day 1 until a hemoglobin (Hb) level of 10 g/dL was achieved, for a maximum of 60 days. In the second trial, rhEpo 500 U/kg/week was given to achieve Hb levels of 13 to 14 g/dL in 13 anemic patients with fatigue 56 to 1440 days after transplant. In the third trial, rhEpo was scheduled to start on day 35 in 14 patients at a dose of 500 U/kg/week with the aim of achieving Hb levels of 13 to 14 g/dL. RESULTS: In trial 1, erythroid recovery to 1% reticulocytes and red blood cell transfusion independence were faster, but the number of transfusions was not reduced compared to 10 controls. Responses were brisk in trial 2, with transfusion independence achieved after a median of 1 week in 12 of 13 patients, and 2-g Hb increments or Hb values of 11, 12, and 13 g/dL after 6, 7, 10, and 10 weeks, respectively. Transfusions were significantly reduced in the first month of rhEpo therapy. In trial 3, transfusion independence was obtained after a median of 1 week in 13 of 14 patients, and 2-g Hb increments or Hb values of 11, 12, and 13 g/dL after 3, 4, 6, and 8 weeks, respectively. Transfusions rates were considerably reduced compared to the previous month in the same patients or compared to controls undergoing peripheral blood or marrow transplant without rhEpo. CONCLUSIONS: Anemia after allogeneic HSCT is exquisitely sensitive to rhEpo. The benefit is minimal when it is given early post-transplant, as used in all trials to date. However, the rate of major response is greater than 90% when rhEpo is started after day 35. These data provide the basis on which to conduct a prospective, randomized, placebo-controlled trial of rhEpo therapy after allogeneic HSCT. [less ▲]

Detailed reference viewed: 37 (2 ULg)
Full Text
Peer Reviewed
See detailAdministration of erythopoietin and granulocyte colony-stimulating factor in donor/recipient pairs to collect peripheral blood progenitor cells (PBPC) and red blood cell units for use in the recipient after allogeneic PBPC transplantation.
Sautois, Brieuc ULg; Baudoux, Etienne ULg; Salmon, Jean ULg et al

in Haematologica (2001), 86(11), 1209-18

BACKGROUND AND OBJECTIVES: It may be useful to reduce the exposure of transplant recipients to homologous blood. This may be achieved by procuring donor-derived red blood cell (RBC) units, collecting more ... [more ▼]

BACKGROUND AND OBJECTIVES: It may be useful to reduce the exposure of transplant recipients to homologous blood. This may be achieved by procuring donor-derived red blood cell (RBC) units, collecting more peripheral blood progenitor cells (PBPC) with a combination of granulocyte colony-stimulating factor (G-CSF) + recombinant human erythropoietin (rHuEpo) and by administering rHuEpo post-transplantation. DESIGN AND METHODS: Eight ABO-compatible donors were treated with rHuEpo and intravenous iron to collect 12 RBC units for use in their recipients. PBPC were collected after mobilization with rHuEpo and G-CSF in the same donors. The recipients received G-CSF and rHuEpo post-transplantation. A control group of 10 donor/recipient pairs received G-CSF alone for PBPC mobilization and after the transplantation. RESULTS: Eighty-six out of 91 planned RBC units were collected in the donors without significant decrease in hematocrit because of a 4-fold increase in RBC production despite functional iron deficiency. After 2 leukaphereses, the cumulative yields of NC and CFU-GM were lower in the study group while those of BFU-E, CFU-Mix and CD34+ cells were similar. However, erythroid recovery was significantly accelerated in the study group. INTERPRETATION AND CONCLUSIONS: Collection of 12 RBC units within 6 weeks is feasible with rHuEpo and intravenous iron; this strategy allows a dramatic reduction in recipient exposure to homologous blood; rHuEpo has no synergistic effect with G-CSF for mobilization of PBPC in normal donors and may even be deleterious; and rHuEpo in the recipient may enhance erythroid engraftment. [less ▲]

Detailed reference viewed: 67 (4 ULg)
Full Text
Peer Reviewed
See detailNouvelles approches thérapeutiques puor l'hypernéphrome métastasique
Sylvestre, Rose-Marie; Jerusalem, Guy ULg; Sautois, Brieuc ULg et al

in Médecine et Hygiène (2001), 59

Detailed reference viewed: 414 (25 ULg)
Full Text
Peer Reviewed
See detailPlace de la tomographie d'émission de positons dans le suivi thérapeutique du cancer du sein
Jerusalem, Guy ULg; Belhocine, Tarik; Silvestre, Rose-Marie et al

in Médecine Nucléaire : Imagerie Fonctionnelle et Métabolique (2001), 25(6), 341-346

La tomographie à émission de positons (TEP) au 18F-fluorodeoxyglucose (FDG) fait l'objet d'un nombre croissant d'applications cliniques en oncologie surtout dans le bilan d'extension et le bilan de fin de ... [more ▼]

La tomographie à émission de positons (TEP) au 18F-fluorodeoxyglucose (FDG) fait l'objet d'un nombre croissant d'applications cliniques en oncologie surtout dans le bilan d'extension et le bilan de fin de traitement. Un domaine très prometteur mais peu étudié est l'utilisation de la TEP dans l'évaluation thérapeutique précoce. Nous passons en revue les données de la littérature concernant la place de la TEP dans l'évaluation précoce de la réponse thérapeutique chez des patientes atteintes de cancer du sein. La TEP permet d'identifier précocement les patientes qui ont une grande probabilité de présenter une réponse tumorale facorable à une chimiothérapie néoadjuvante (chimiothérapie première). Cependant, non propres travaux chez des patientes atteintes de cancer du sein métastatique sont moins prometteurs. La poursuite des travaux de recherche est indispensable pour mieux connaître le bénéfice réel et les limites d'une évaluation thérapeutique précoce. [less ▲]

Detailed reference viewed: 43 (3 ULg)
Peer Reviewed
See detailComment je traite ... le myelome multiple refractaire par thalidomide
Scerbo, F.; Matus, G.; Sautois, Brieuc ULg et al

in Revue Médicale de Liège (2000), 55(11), 970-3

Despite the use of high-dose chemotherapy with autologous hematopoietic stem cell transplantation, multiple myeloma remains largely uncurable. Indeed complete remission rate is about 50% and median ... [more ▼]

Despite the use of high-dose chemotherapy with autologous hematopoietic stem cell transplantation, multiple myeloma remains largely uncurable. Indeed complete remission rate is about 50% and median survival reaches 5 years without plateau. Recently thalidomide has been identified as a promising agent. We report the clinical story of 2 patients with refractory myeloma that we treated successfully with thalidomide. [less ▲]

Detailed reference viewed: 84 (3 ULg)
Full Text
Peer Reviewed
See detailSuccessful mobilization of peripheral blood HPCs with G-CSF alone in patients failing to achieve sufficient numbers of CD34+ cells and/or CFU-GM with chemotherapy and G-CSF.
Fraipont, V.; Sautois, Brieuc ULg; Baudoux, Etienne ULg et al

in Transfusion (2000), 40(3), 339-47

BACKGROUND: Mobilization with chemotherapy and G-CSF may result in poor peripheral blood HPC collection, yielding <2 x 10(6) CD34+ cells per kg or <10 x 10(4) CFU-GM per kg in leukapheresis procedures ... [more ▼]

BACKGROUND: Mobilization with chemotherapy and G-CSF may result in poor peripheral blood HPC collection, yielding <2 x 10(6) CD34+ cells per kg or <10 x 10(4) CFU-GM per kg in leukapheresis procedures. The best mobilization strategy for oncology patients remains unclear. STUDY DESIGN AND METHODS: In 27 patients who met either the CD34 (n = 3) or CFU-GM (n = 2) criteria or both (n = 22), the results obtained with two successive strategies-that is, chemotherapy and G-CSF at 10 microg per kg (Group 1, n = 7) and G-CSF at 10 microg per kg alone (Group 2, n = 20) used for a second mobilization course-were retrospectively analyzed. The patients had non-Hodgkin's lymphoma (5), Hodgkin's disease (3), multiple myeloma (5), chronic myeloid leukemia (1), acute myeloid leukemia (1), breast cancer (6), or other solid tumors (6). Previous therapy consisted of 10 (1-31) cycles of chemotherapy with additional chlorambucil (n = 3), interferon (n = 3), and radiotherapy (n = 7). RESULTS: The second collection was undertaken a median of 35 days after the first one. In Group 1, the results of the two mobilizations were identical. In Group 2, the number of CD34+ cells per kg per apheresis (0.17 [0.02-0.45] vs. 0.44 [0.11-0.45], p = 0. 00002), as well as the number of CFU-GM (0.88 [0.00-13.37] vs. 4.19 [0.96-21.61], p = 0.00003), BFU-E (0.83 [0.00-12.72] vs. 8.81 [1. 38-32.51], p = 0.00001), and CFU-MIX (0.10 [0.00-1.70] vs. 0.56 [0. 00-2.64], p = 0.001134) were significantly higher in the second peripheral blood HPC collection. However, yields per apheresis during the second collection did not significantly differ in the two groups. Six patients in Group 1 and 18 in Group 2 underwent transplantation, and all but one achieved engraftment, with a median of 15 versus 12 days to 1,000 neutrophils (NS), 22 versus 16 days to 1 percent reticulocytes (NS), and 26 versus 26 days to 20,000 platelets (NS), respectively. However, platelet engraftment was particularly delayed in many patients. CONCLUSION: G-CSF at 10 microg per kg alone may constitute a valid alternative to chemotherapy and G-CSF to obtain adequate numbers of peripheral blood HPCs in patients who previously failed to achieve mobilization with chemotherapy and G-CSF. This strategy should be tested in prospective randomized trials. [less ▲]

Detailed reference viewed: 111 (10 ULg)
Full Text
Peer Reviewed
See detailTraitement des myélomes réfractaires par la Thalidomide
Sautois, Brieuc ULg; Scerbo, Franca; Beguin, Yves ULg et al

in Médecine et Hygiène (2000), 58

Detailed reference viewed: 29 (2 ULg)
Full Text
Peer Reviewed
See detailL'image du mois. Purpura thrombocytopenique auto-immun.
Smitz, Simon ULg; Neven, I.; Sautois, Brieuc ULg et al

in Revue Médicale de Liège (1999), 54(8), 645

Detailed reference viewed: 6 (0 ULg)
Full Text
Peer Reviewed
See detailPeripheral blood progenitor cell collections in cancer patients: analysis of factors affecting the yields.
Sautois, Brieuc ULg; Fraipont, V.; Baudoux, Etienne ULg et al

in Haematologica (1999), 84(4), 342-9

BACKGROUND AND OBJECTIVE: Peripheral blood progenitor cells (PBPC) are now widely used to restore hematopoiesis following high dose chemotherapy in patients with malignancies. We sought to identify ... [more ▼]

BACKGROUND AND OBJECTIVE: Peripheral blood progenitor cells (PBPC) are now widely used to restore hematopoiesis following high dose chemotherapy in patients with malignancies. We sought to identify parameters that could predict the yield of PBPC after mobilization with chemotherapy (CT) with or without granulocyte colony-stimulating factor (G-CSF) in cancer patients. DESIGN AND METHODS: One hundred and fifty patients underwent 627 PBPC collections during the recovery phase following CT with (n = 469) or without (n = 142) G-CSF. Hemogram, CFC-assays and CD34+ cell count were performed on peripheral blood and leukaphereses products. After log transformation of the data, differences between groups were assessed with the unpaired t-test or one-way analysis of variance. RESULTS: Seventeen and two patients required 2 and 3 mobilization cycles respectively to reach our target of 15x10(4) CFU-GM/kg. In patients with lymphoma but not in those with leukemia, the yields of both CFU-GM and CD34+ cells/kg were dramatically increased when G-CSF was added to CT for mobilization. In collections primed with CT and G-CSF, better yields were obtained in patients with breast cancer or small-cell lung carcinoma (SCLC) as opposed to other solid tumors and leukemia. Among potential predictive factors of CT- and G-CSF-primed harvests, we found that the CD34+ cell count in peripheral blood (PB) was strongly correlated with both the CFU-GM and CD34+ cell yields. Except in leukemia patients, more than 1x10(6) CD34+ cells/kg were harvested when the CD34+ cell count in blood was above 20x10(6)/L. Similarly, better results were obtained in collections performed when the percentage of myeloid progenitors in blood on the day of apheresis was above 5 % or when the leukocyte count in blood was above 5x10(9)/L. INTERPRETATION AND CONCLUSIONS: A diagnosis of breast cancer or SCLC, a leukocyte count in PB of more than 5x10(9)/L, more than 5% myeloid progenitors or more than 20x10(6) CD34+ cells/L in PB were associated with higher yields of PBPC in collections mobilized with CT+G-CSF. [less ▲]

Detailed reference viewed: 80 (10 ULg)
Peer Reviewed
See detailHematopoietic recovery in cancer patients after transplantation of autologous peripheral blood CD34+ cells or unmanipulated peripheral blood stem and progenitor cells.
Beguin, Yves ULg; Baudoux, Etienne ULg; Sautois, Brieuc ULg et al

in Transfusion (1998), 38(2), 199-208

BACKGROUND: A study of CD34+ cell selection and transplantation was carried out with particular emphasis on characteristics of short- and long-term hematopoietic recovery. STUDY DESIGN AND METHODS ... [more ▼]

BACKGROUND: A study of CD34+ cell selection and transplantation was carried out with particular emphasis on characteristics of short- and long-term hematopoietic recovery. STUDY DESIGN AND METHODS: Peripheral blood stem and progenitor cells (PBPCs) were collected from 32 patients, and 17 CD34+ cell-selection procedures were carried out in 15 of the 32. One patient in whom two procedures failed to provide 1 x 10(6) CD34+ cells per kg was excluded from further analysis. After conditioning, patients received CD34+ cells (n = 10, CD34 group) or unmanipulated (n = 17, PBPC group) PBPCs containing equivalent amounts of CD34+ cells or progenitors. RESULTS: The yield of CD34+ cells was 53 percent (18-100) with a purity of 63 percent (49-82). The CD34+ fraction contained 66 percent of colony-forming units--granulocyte-macrophage (CFU-GM) and 58 percent of CFU of mixed lineages, but only 33 percent of burst-forming units-erythroid (BFU-E) (p < 0.05). Early recovery of neutrophils and reticulocytes was identical in the two groups, although a slight delay in platelet recovery may be seen with CD34+ cell selection. Late hematopoietic reconstitution, up to 1.5 years after transplant, was also similar. The two groups were thus combined for analyses of dose effects. A dose of 40 x 10(4) CFU-GM per kg ensured recovery of neutrophils to a level of 1 x 10(9) per L within 11 days, 15 x 10(4) CFU of mixed lineages per kg was associated with platelet independence within 11 days, and 100 x 10(4) BFU-E per kg predicted red cell independence within 13 days. However, a continuous effect of cell dose well beyond these thresholds was apparent, at least for neutrophil recovery. CONCLUSION: CD34+ cell selection, despite lower efficiency in collecting BFU-E, provides a suitable graft with hematopoietic capacity comparable to that of unmanipulated PBPCs. In both groups, all patients will eventually show hematopoietic recovery of all three lineages with 1 x 10(6) CD34+ cells per kg or 5 x 10(4) CFU-GM per kg, but a dose of 5 x 10(6) CD34+ cells or 40 x 10(4) CFU-GM per kg is critical to ensure rapid recovery. [less ▲]

Detailed reference viewed: 52 (9 ULg)
Full Text
Peer Reviewed
See detailAcute Functional Iron Deficiency in Obese Subjects During a Very-Low-Energy All-Protein Diet
Beguin, Yves ULg; Grek, Vincent; Weber, Georges ULg et al

in American Journal of Clinical Nutrition (1997), 66(1), 75-9

We examined whether a very-low-energy all-protein diet (VLED) would produce detectable changes in iron as well as in other trace elements. Twenty-five obese patients consumed for 2 wk a VLED containing 70 ... [more ▼]

We examined whether a very-low-energy all-protein diet (VLED) would produce detectable changes in iron as well as in other trace elements. Twenty-five obese patients consumed for 2 wk a VLED containing 70 g protein after a 1-wk period during which total daily energy intake was progressively reduced to 1.26 MJ. Serum iron fell sharply by approximately equal to 50% (P < 0.0001), and despite a small decrease in total-iron-binding capacity, transferrin saturation decreased from 30 +/- 11% to 18 +/- 5% (P < 0.0001). Serum ferritin did not change significantly but serum soluble transferrin receptor (sTfR), an indicator of iron deficiency, increased progressively from 4630 +/- 1110 to 6070 +/- 1390 micrograms/L (P < 0.0001). Changes in sTfR correlated inversely with prior changes in serum iron. Changes in iron metabolism did not translate into changes in erythropoiesis or red cell indexes, but the white blood cell count decreased from 7.3 +/- 1.6 to 6.2 +/- 1.9 x 10(9)/L (P < 0.002). There was no evidence of deficiency for the other trace elements and minerals tested. Daily supplementation with 200 mg Fe in 18 other subjects only partially corrected these observations despite some increase in iron stores. These results indicate that during a 2-wk VLED serum iron is significantly depressed, inducing functional tissue iron deficiency too short in duration to produce alterations in red blood cell indexes. These changes are not mediated by absolute iron deficiency, inflammation, or protein malnutrition but could be related to alterations in the iron storage and release behavior of the reticuloendothelial cell during energy deprivation alone. [less ▲]

Detailed reference viewed: 76 (11 ULg)